Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Pfizer

Pharma Rally Continues As Pfizer, Amgen Look To Break Out, Pulling Rivals With Them

A handful of pharmaceutical stocks — including Pfizer and Amgen — are either eyeing buy points or have broken out after diving in June.

Investors Business Daily

A new COVID-19 foe, a really transmissible one, is emerging

BALTIMORE — If you’ve recently been infected with COVID-19 or know someone infected, and you probably do, you can probably blame BA.5, one of five subvariants of omicron and possibly the most transmissible yet.

Tribune News Service

EU backs second COVID booster for over-60s, before variant-adapted vaccines are ready

European Union health agencies on Monday recommended a second COVID-19 booster for everyone over 60, as well as medically vulnerable people, amid a new rise in infections and hospitalisations across Europe.

Reuters

From analysis to the latest developments in health,
read the most diverse news in one place.

Ask the Pediatrician: What should parents know about COVID-19 vaccine for children under 5?

Q: I have heard that there’s an approved COVID-19 vaccine for children under 5. What do I need to know about it?

Tribune News Service

The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Medical Sector Leads New Buys By Top Funds While Big Mac Joins Big Oil

As tech titans like Apple and Nvidia get shunned again, the best mutual funds focus on Big Pharma and biotech stocks.

Investors Business Daily

Warning Shots: CureVac Sues BioNTech Over COVID Vax Patents

Pharma giants CureVac are suing Pfizer’s vaccine partner BioNTech over the development of the vaccine credited with saving the world from COVID19.

Zenger

Read news from The Economist, FT, and more,
with one subscription

Thinking of mixing and matching COVID-19 vaccine booster shots? There doesn't seem to be much point

Most people will have the Moderna or the Pfizer vaccine for their fourth dose. But the Doherty Institute's head of vaccine and immunisation research says there's practically no difference between them.

ABC News

The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Africa CDC signs with Pfizer for COVID pill for African countries

Pfizer will now supply the COVID-19 pill that is highly effective in preventing hospitalisations and deaths.

Al Jazeera

Low Stock Prices, High Yields Fuel This Fund's Market Beat

True to its name, DWS CROCI Equity Dividend Fund makes good use of dividend stocks. The fund's trailing 12-month yield was 2.45%, going into Tuesday.

Investors Business Daily

Australia’s booster doses explained: how to decide if you should get a fourth Covid vaccine and how long to wait

How long should I wait after a third dose? Should I wait for an Omicron-specific vaccine? Your questions answered

The Guardian - AU

COVID-19 boosters 'a matter of urgency' says Prime Minister as infections rise to highest level since February

Australia is expected to follow other parts of the world in expanding eligibility for a fourth COVID-19 vaccine dose to the wider population, with the Prime Minister saying the pandemic "isn't over" while encouraging eligible Australians to get their booster shots.

ABC News

Pfizer vaccines that target Omicron variant pass first step to approval in Australia

The TGA’s ‘provisional determination’ for two vaccines comes as BA.4 and BA.5 subvariants drive new wave of Covid cases

The Guardian - AU

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot

Pfizer stock crashed into its 50-day line Tuesday after Germany's CureVac sued its Covid vaccine partner, BioNTech, for patent infringement.

Benzinga

What Are Whales Doing With Pfizer

A whale with a lot of money to spend has taken a noticeably bearish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 11 strange trades.

Tribune News Service

How Pfizer won the pandemic, reaping outsize profit and influence

The grinding two-plus years of the pandemic have yielded outsize benefits for one company — Pfizer — making it both highly influential and hugely profitable as COVID-19 continues to infect tens of thousands of people and kill hundreds each day.

StockNews.com

As Covid Cases Decline, is it Time to Drop Pfizer?

Leading drug maker Pfizer (PFE) experienced robust growth over the past year primarily based on the growing demand for its Covid vaccine. However, as Covid cases decline, will the company be able to maintain its growth trajectory? Let’s find out.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

What’s the UK’s booster policy ahead of a feared autumn Covid wave?

Tweaked vaccines to tackle Omicron are in trials as JCVI finalises advice for vulnerable groups

WEKU

FDA says COVID boosters for the fall must target newer omicron types

With immunity waning and the super-contagious omicron family of variants getting better at dodging protection, the Food and Drug Administration decided boosters intended for fall needed an update.

Benzinga

Why Pfizer Stock Is Rising Today

Pfizer Inc (NYSE: PFE) shares are trading higher Thursday after the company and BioNTech SE (NASDAQ: BNTX) announced a new COVID-19 vaccine supply agreement with the U.S. government.

Benzinga

This Analyst Says US Government Buying More COVID-19 Vaccines At Higher Prices

Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced a new COVID-19 vaccine supply agreement with the U.S. government. SVB Leerink says that the new contract implies the price per Comirnaty dose is ~$30.50. Comirnaty U.S. pricing per dose has increased from $19.50 (2020 contracts), to $24 (+23%; 2021 contract), and now to ~$30.50 (+27%). The analysts…

Benzinga

Pfizer Seeks Complete Approval For Paxlovid For High Risk COVID-19 Patients

Pfizer Inc (NYSE:PFE) has submitted a new drug application to the FDA for the approval of Paxlovid for patients at high risk for progression to severe illness from COVID-19. Paxlovid is currently authorized for emergency use to treat mild-to-moderate COVID-19 in adults and pediatric patients at high risk for progression to severe COVID-19,…

Benzinga

Will Palantir, Pfizer And Oracle Stocks Continue Higher In This Trend?

Oracle Corporation (NYSE: ORCL), Pfizer Inc (NYSE: PFE) and Palantir Technologies Inc (NYSE: PLTR) were all trading near to fla

Investors Business Daily

The FDA Just Handed BioNTech And Moderna A Gift — But Only One Jumped

The FDA requested vaccine makers update their Covid shots to include an omicron-fighting element on Thursday, and BNTX stock surged.

1 … 42 43 44 45

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.